Fenfen Zhou1, Therwa Hamza2, Ashley S Fleur2, Yongrong Zhang2, Hua Yu2, Kevin Chen2, Jonathon E Heath3, Ye Chen4, Haihui Huang1, Hanping Feng2. 1. Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China. 2. Department of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, Maryland, USA. 3. Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA. 4. Department of Gastroenterology, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Abstract
Background: Over the past several decades, there has been a significant increase in the incidence of Clostridium difficile infection (CDI) in patients suffering from inflammatory bowel disease (IBD). However, a wild-type animal model is not available to study these comorbid diseases. Methods: We evaluated the susceptibility to CDI of mice with dextran sulfate sodium salt (DSS)-induced colitis (IBD mice) with or without antibiotic exposure; we examined the histopathology and cytokine response in the concomitant diseases after the model was created. Results: No CDI occurs in healthy control mice, wherease the incidence of CDI in IBD mice is 40%; however, in IBD mice that received antibiotics, the incidence of CDI is 100% and the disease is accompanied by high levels of toxins in the mouse feces and sera. Compared to IBD and CDI alone, those IBD mice infected with C. difficile have more severe symptoms, toxemia, histopathological damage, and higher mortality. Moreover, several proinflammatory cytokines and chemokines are significantly elevated in the colon tissues from IBD mice infected with C. difficile. Conclusions: We, for the first time, demonstrate in an animal model that mice with dextran sulfate sodium induced-inflammatory bowel disease are significantly more susceptible to C. difficile infection, and that the bacterial infection led to more severe disease and death. These findings are consistent with clinical observations, thus, the animal model will permit us to study the pathogenesis of these concurrent diseases and to develop therapeutic strategies against the comorbidity of IBD and CDI.
Background: Over the past several decades, there has been a significant increase in the incidence of Clostridium difficile infection (CDI) in patients suffering from inflammatory bowel disease (IBD). However, a wild-type animal model is not available to study these comorbid diseases. Methods: We evaluated the susceptibility to CDI of mice with dextran sulfate sodium salt (DSS)-induced colitis (IBD mice) with or without antibiotic exposure; we examined the histopathology and cytokine response in the concomitant diseases after the model was created. Results: No CDI occurs in healthy control mice, wherease the incidence of CDI in IBD mice is 40%; however, in IBD mice that received antibiotics, the incidence of CDI is 100% and the disease is accompanied by high levels of toxins in the mouse feces and sera. Compared to IBD and CDI alone, those IBD mice infected with C. difficile have more severe symptoms, toxemia, histopathological damage, and higher mortality. Moreover, several proinflammatory cytokines and chemokines are significantly elevated in the colon tissues from IBD mice infected with C. difficile. Conclusions: We, for the first time, demonstrate in an animal model that mice with dextran sulfate sodium induced-inflammatory bowel disease are significantly more susceptible to C. difficileinfection, and that the bacterial infection led to more severe disease and death. These findings are consistent with clinical observations, thus, the animal model will permit us to study the pathogenesis of these concurrent diseases and to develop therapeutic strategies against the comorbidity of IBD and CDI.
Authors: Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun Journal: Am J Gastroenterol Date: 2013-02-26 Impact factor: 10.864
Authors: Evelyn M Clayton; Mary C Rea; Fergus Shanahan; Eamonn M M Quigley; Barry Kiely; Colin Hill; R Paul Ross Journal: Am J Gastroenterol Date: 2009-03-24 Impact factor: 10.864
Authors: Xochitl C Morgan; Timothy L Tickle; Harry Sokol; Dirk Gevers; Kathryn L Devaney; Doyle V Ward; Joshua A Reyes; Samir A Shah; Neal LeLeiko; Scott B Snapper; Athos Bousvaros; Joshua Korzenik; Bruce E Sands; Ramnik J Xavier; Curtis Huttenhower Journal: Genome Biol Date: 2012-04-16 Impact factor: 13.583
Authors: R Panaccione; J-F Colombel; W J Sandborn; G D'Haens; Q Zhou; P F Pollack; R B Thakkar; A M Robinson Journal: Aliment Pharmacol Ther Date: 2013-09-22 Impact factor: 8.171
Authors: Mahmoud M Saleh; Alyse L Frisbee; Jhansi L Leslie; Erica L Buonomo; Carrie A Cowardin; Jennie Z Ma; Morgan E Simpson; Kenneth W Scully; Mayuresh M Abhyankar; William A Petri Journal: Cell Host Microbe Date: 2019-04-16 Impact factor: 21.023
Authors: Joshua R Fletcher; Colleen M Pike; Ruth J Parsons; Alissa J Rivera; Matthew H Foley; Michael R McLaren; Stephanie A Montgomery; Casey M Theriot Journal: Nat Commun Date: 2021-01-19 Impact factor: 14.919
Authors: Lisa Abernathy-Close; Madeline R Barron; James M George; Michael G Dieterle; Kimberly C Vendrov; Ingrid L Bergin; Vincent B Young Journal: mBio Date: 2021-06-15 Impact factor: 7.867